A new partnership to improve TB treatments around the world

Find out about the endTB clinical trial results here

endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

access to new drugs
two clinical trials
advocacy at national and global levels.

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF.

You can contact us, or follow us on Twitter.

Watch the two-minute animation

endTB clinical trial results - VIDEO

The endTB clinical trial results are out! This landmark trial offers multiple new shortened, all-oral drug regimens to treat adults and children with MDR-TB.

The video is now also available with Spanish, French and Russian subtitles.

Read our press release and more here

Major advance in the fight against MDR-TB: four new short and effective treatments approved by the WHO

Paris, 19 August 2024 - In a rapid communication, the World Health Organization (WHO) recommended 3 new regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB), which were studied in the endTB clinical trial. This is a breakthrough in the fight against MDR-TB worldwide.